Applying support-vector machine learning algorithms toward predicting host-guest interactions with cucurbit[7]uril.
暂无分享,去创建一个
Thomas Gebhart | Polina Anikeeva | Oren A Scherman | Harry Bulstrode | Guanglu Wu | Anthony Tabet | Charlie Readman | Merrick Pierson Smela | Vijay K Rana | Cole Baker | David H Rowitch | D. Rowitch | P. Anikeeva | O. Scherman | H. Bulstrode | Guanglu Wu | A. Tabet | Charlie A. Readman | V. Rana | Thomas Gebhart | Merrick Pierson Smela | Cole Baker
[1] O. Scherman,et al. Enhanced stability and activity of temozolomide in primary glioblastoma multiforme cells with cucurbit[n]uril. , 2012, Chemical communications.
[2] A. Bernkop‐Schnürch,et al. Strategies to improve plasma half life time of peptide and protein drugs , 2006, Amino Acids.
[3] M. Frisch,et al. Ab Initio Calculation of Vibrational Absorption and Circular Dichroism Spectra Using Density Functional Force Fields , 1994 .
[4] Pieter P. Plehiers,et al. A robotic platform for flow synthesis of organic compounds informed by AI planning , 2019, Science.
[5] D. Matak-Vinkovic,et al. Mining 2:2 Complexes from 1:1 Stoichiometry: Formation of Cucurbit[8]uril-Diarylviologen Quaternary Complexes Favored by Electron-Donating Substituents. , 2017, Journal of the American Chemical Society.
[6] E. Rosta,et al. Cucurbit[7]uril as a Supramolecular Artificial Enzyme for Diels-Alder Reactions. , 2017, Angewandte Chemie.
[7] V. Sondak,et al. Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma , 2013, Nature Reviews Clinical Oncology.
[8] Michael J. Keiser,et al. Comment on “Predicting reaction performance in C–N cross-coupling using machine learning” , 2018, Science.
[9] Q. Lan,et al. CSIG-19. FHL2 INTERACTS WITH EGFRVIII TO PROMOTE GLIOBLASTOMA GROWTH , 2017 .
[10] David L. Mobley,et al. The SAMPL4 host–guest blind prediction challenge: an overview , 2014, Journal of Computer-Aided Molecular Design.
[11] P. Patil,et al. Designing Next‐Generation Local Drug Delivery Vehicles for Glioblastoma Adjuvant Chemotherapy: Lessons from the Clinic , 2019, Advanced healthcare materials.
[12] Regina Barzilay,et al. Prediction of Organic Reaction Outcomes Using Machine Learning , 2017, ACS central science.
[13] Geoffrey E. Hinton,et al. Visualizing Data using t-SNE , 2008 .
[14] Erkki Ruoslahti,et al. Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs , 2010, Science.
[15] O. Scherman,et al. Mechanical Characterization of Human Brain Tissue and Soft Dynamic Gels Exhibiting Electromechanical Neuro‐Mimicry , 2019, Advanced healthcare materials.
[16] Masoumeh Haghpanahi,et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network , 2019, Nature Medicine.
[17] Sebastian Thrun,et al. Dermatologist-level classification of skin cancer with deep neural networks , 2017, Nature.
[18] Chun Wang,et al. Gels without Vapor Pressure: Soft, Nonaqueous, and Solvent‐Free Supramolecular Biomaterials for Prospective Parenteral Drug Delivery Applications , 2018, Advanced healthcare materials.
[19] Oren A Scherman,et al. Cucurbituril-Based Molecular Recognition. , 2015, Chemical reviews.
[20] C. Abell,et al. Biomimetic Supramolecular Polymer Networks Exhibiting both Toughness and Self‐Recovery , 2017, Advanced materials.
[21] Nan Li,et al. Tough Supramolecular Polymer Networks with Extreme Stretchability and Fast Room‐Temperature Self‐Healing , 2017, Advanced materials.
[22] W. Hahn,et al. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas , 2017, Neuro-oncology.
[23] Shengke Li,et al. Cucurbit[7]uril: an emerging candidate for pharmaceutical excipients , 2017, Annals of the New York Academy of Sciences.
[24] R. Fisher,et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma , 2019, Nature Medicine.
[25] Connor W. Coley,et al. Machine Learning in Computer-Aided Synthesis Planning. , 2018, Accounts of chemical research.
[26] M. Prados,et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study , 2017, Neuro-oncology.